These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33322052)

  • 61. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
    Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
    Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
    [No Abstract]   [Full Text] [Related]  

  • 62. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
    Ghufran M; Ullah M; Khan HA; Ghufran S; Ayaz M; Siddiq M; Abbas SQ; Hassan SSU; Bungau S
    Bioengineering (Basel); 2023 Jan; 10(1):. PubMed ID: 36671672
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
    Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
    J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Receptor-Based Pharmacophore Modeling in the Search for Natural Products for COVID-19 M
    Saeed M; Saeed A; Alam MJ; Alreshidi M
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33799871
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal.
    Proia E; Ragno A; Antonini L; Sabatino M; Mladenovič M; Capobianco R; Ragno R
    J Comput Aided Mol Des; 2022 Jul; 36(7):483-505. PubMed ID: 35716228
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification of Severe Acute Respiratory Syndrome Coronavirus-2 inhibitors through in silico structure-based virtual screening and molecular interaction studies.
    Azad I; Khan T; Maurya AK; Irfan Azad M; Mishra N; Alanazi AM
    J Mol Recognit; 2021 Oct; 34(10):e2918. PubMed ID: 34132436
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.
    Nand M; Maiti P; Joshi T; Chandra S; Pande V; Kuniyal JC; Ramakrishnan MA
    Sci Rep; 2020 Nov; 10(1):20397. PubMed ID: 33230180
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
    Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
    Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Discovery of Small Allosteric and Active Site Inhibitors of the SARS-CoV-2 Main Protease via Structure-Based Virtual Screening and Biological Evaluation.
    Mahgoub RE; Mohamed FE; Alzyoud L; Ali BR; Ferreira J; Rabeh WM; AlNeyadi SS; Atatreh N; Ghattas MA
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235244
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
    Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an
    Mahanta S; Chowdhury P; Gogoi N; Goswami N; Borah D; Kumar R; Chetia D; Borah P; Buragohain AK; Gogoi B
    J Biomol Struct Dyn; 2021 Jul; 39(10):3802-3811. PubMed ID: 32406317
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
    Hicks EG; Kandel SE; Lampe JN
    Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").
    Cayona R; Creencia E
    Med Chem; 2022; 18(3):364-381. PubMed ID: 34148541
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sterenin M as a potential inhibitor of SARS-CoV-2 main protease identified from MeFSAT database using molecular docking, molecular dynamics simulation and binding free energy calculation.
    Prajapati J; Patel R; Goswami D; Saraf M; Rawal RM
    Comput Biol Med; 2021 Aug; 135():104568. PubMed ID: 34174757
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
    Refaey RH; El-Ashrey MK; Nissan YM
    Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.
    Varadharajan V; Arumugam GS; Shanmugam S
    J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacophore based virtual screening for natural product database revealed possible inhibitors for SARS-COV-2 main protease.
    El-Ashrey MK; Bakr RO; Fayed MAA; Refaey RH; Nissan YM
    Virology; 2022 May; 570():18-28. PubMed ID: 35339903
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.